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ox-Fordyce disease (FFD) (also known as
apocrine miliaria) is a rare dermatologic con-
dition characterized by multiple skin-colored,
equidistant, perifollicular papules distributed in
areas rich in apocrine glands. These areas typically
include the axillae, anogenital, and periareolar
regions.1 This condition primarily affects young
females between 15 and 35 years of age, and rarely
presents before puberty. The disease is often
severely pruritic and may be exacerbated by
sympathetic stimulation such as stress, exercise,
excitement, and hot weather.1-3 The diagnosis is
typically made clinically but histopathologic exami-
nation may display infundibular plugging, paraker-
atosis, spongiosis, and acanthosis.4,5 Perifollicular
foam cells are now believed to be a distinct and
specific feature of FFD.4 Therapeutic modalities are
commonly lackluster and no definitive treatment
exists for this entity.
MiraDry (Miramar Labs Incorporated, Santa Clara,
CA) is a novel microwave device that was recently
approved by the Food and Drug Administration
in 2011 for the treatment of primary axillary
hyperhidrosis. It targets the eccrine, apocrine, and
apoeccrine sweat glands in addition to hair follicles
by targeting the dermal-hypodermal junction
through dielectric heating.6 We report a case of
axillary FFD treated with this novel noninvasive
microwave technology.
CASE REPORT
A 25-year-old female presented with a 2-year
history of pruritic papules in the bilateral axillae.
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icago, IL 60612. E-mail: drewmt22@gmail.com.exercise and stress. She had been using a sensitive
skin deodorant and denied any changes in her
shaving cream or razor. The patient also denied
any changes to her axillary sweating patterns or
volume. There was no history of axillary hair
removal procedures or family history of similar
lesions. On physical examination, she had multiple,
monomorphic, flesh-colored to yellow, conical
papules in the bilateral axillary vaults, with extension
to the axillary folds.
The patient was clinically diagnosed with FFD.
Initially, tretinoin 0.1% cream was started to the
affected areas daily, but she returned after 3 months
without any improvement in appearance or pruritus.
At this time, MiraDry microwave technology
(Miramar Labs Inc), given its capability to target
hair follicles, eccrine, apocrine, and apoeccrine
sweat glands was recommended to the patient.
The procedure consisted of several steps: delin-
eation of the axillary vault with a treatment template
based on the individual size of the axilla (ranging
from 60-120 mm), injection of 17 mL of local
anesthetic (1% lidocaine with 1:100,000 epineph-
rine) in the dermis of each axilla, followed by
injection of 40 mL of sterile saline into the upper
half of each axilla, and treatment with the microwave
MiraDry system (Miramar Labs Inc) at a selected
energy level. We utilized an energy level of 3 for the
first treatment session followed by a maximum
energy level of 5 for the second treatment 9 months
later. The patient developed the expected sequelae
from the procedure including: temporary pain,
swelling, and bruising, which resolved within 5 to
7 days after the procedure. The longer-term effectsJAAD Case Reports 2016;2:1-3.
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Fig 1. Left axilla at baseline (A) and 2 months after the second treatment (B).
Fig 2. Right axilla at baseline (A) and 2 months after the second treatment (B).
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that resolved within 4 to 6 weeks for the left axilla,
but has persisted, although improved, in the right
axilla 4 months after the second treatment. The
patient denied any accompanying muscle weakness
of the right upper extremity.
The patient had marginal improvement of the
symptomatic lesions after the first treatment, but
significant clearance after the second treatment was
achieved at a higher energy setting (Figs 1 and 2).
The pruritus resolved after the second treatment
session, with a dramatic impact in her quality of life.
In addition, there was a marked decrease in the
axillary hair density after 2 treatment sessions. There
was no evidence of recurrence at the 4-month
follow-up.
DISCUSSION
FFD was first described by George Henry Fox and
John Addison Fordyce7 in the early 20th century. It
is believed that the primary pathophysiologic
process involves a hyperkeratotic plug causing
infundibular obstruction with resultant dilation of
the apocrine duct.1 This may lead to formation of a
retention cyst, ductal rupture, and subsequent
inflammatory response to the spewed material.1The lymphohistiocytic infiltrate may be the cause
of the intense pruritus that often accompanies the
lesions.3,4,8 The precise pathogenesis of FFD remains
unknown but hormonal factors, genetics, and stress
are all thought to be contributors.1
Currently, there has yet to be a consistently
effective treatment for FFD. However, many different
therapeutic modalities have shown variable efficacy
in small subsets of patients. These include topical
clindamycin, oral contraceptives, topical and
oral retinoids, topical pimecrolimus, topical and
intralesional corticosteroids, excision-liposuction
with curettage, and fractional carbon-dioxide laser.1
Because the pathophysiology of FFD is now
believed to be follicularly driven, we hypothesized
that the thermolysis of hair follicles and sweat glands
may potentially alter this pathogenic pathway.
Therefore, we looked to a new noninvasive
technology device that uses microwave energy to
preferentially target the dermal-hypodermal junc-
tion. This microwave device, currently marketed as
MiraDry (Miramar Labs Inc), emits a 5800 Megahertz
microwave frequency to cause dielectric heating
at the dermal-hypodermal junction resulting in
destruction of the sweat glands and hair follicles.6
Application of concurrent contact cooling to the
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thermolysis to the dermal-subcutaneous interface,
between the cooled upper layers and the inert
subcutaneous tissue.
To our knowledge, this is the first reported case
of successfully treating FFD using noninvasive
microwave technology. We observed a decrease in
the number of papules, hair density, and sweating of
the treated areas with complete resolution of the
associated pruritus. Further follow-up showed no
signs of recurrence and the patient continues to be
extremely satisfied with the therapeutic outcome.
The average gravimetric sweat reduction for patients
treated with MiraDry (Miramar Labs Inc) is reported
to be 82% at 12 months and may explain why we
were unable to achieve complete clearance of the
lesions.6 The residual folliculo-sebaceous-apocrine
units may not have reached the temperature
threshold necessary to achieve thermal ablation,
and thus are susceptible to the underlying pathologic
pathway. A third treatment session at a maximum
energy level will be performed. This procedure is
generally not covered by insurance and may cost
$1000-2000 per treatment. Larger scale studies andlong-term follow-up are warranted to determine this
treatment’s efficacy.REFERENCES
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